To include your compound in the COVID-19 Resource Center, submit it here.

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed syndicate designed to support the Netherlands-based coagulation play through registrational studies for its lead program.

INKEF Capital and Ysios Capital co-led the round, joined by fellow new investors LSP and Lundbeckfonden Ventures

Read the full 453 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers